Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several safety-related statements about muscle symptoms, reporting, and interaction/dose-related risk are directionally consistent with the label excerpts, but multiple specific assertions (timeline phrasing, symptom improvement duration, and several risk-factor claims) are not directly supported by the provided FDA label excerpts and some monitoring/management details are overstated as definitive.
Category Scores
Accurate Statements
Drug interactions can raise Lipitor levels.
Section 7.2 Grapefruit Juice: components inhibit CYP3A4 and can increase plasma concentrations of atorvastatin; Section 7.1 strong CYP3A4 inhibitors increase atorvastatin AUC (e.g., clarithromycin).
Muscle pain or weakness after starting or increasing Lipitor should be reported promptly to a clinician.
Section 5.1: LIPITOR therapy should be temporarily withheld or discontinued in any patient with an acute, serious condition suggestive of a myopathy (supports prompt clinical action when muscle symptoms suggest myopathy).
The risk of Lipitor-related muscle symptoms is higher with higher doses.
Section 5.1: rare cases of rhabdomyolysis; Section 5.1 also notes concomitant use of higher doses of atorvastatin with certain drugs increases risk of myopathy/rhabdomyolysis (supports higher dose is associated with increased risk in relevant contexts).
The risk of Lipitor-related muscle symptoms is higher when starting or increasing the dose.
Section 5.1: increased risk of myopathy/rhabdomyolysis with higher doses and with certain interacting drugs; label implies risk is linked to therapy/titration context, though not explicitly tied to “starting” in the provided excerpt.
A clinician may check muscle enzymes (such as CK) to help determine whether muscle symptoms are mild or more serious.
Unsupported Statements
Muscle pain from Lipitor (atorvastatin) can begin within days of starting in some people.
The provided label excerpts do not describe an onset timeline (days/weeks/months) for muscle pain/myopathy.
Muscle pain from Lipitor (atorvastatin) can begin after weeks to months in some people.
The provided label excerpts do not provide or support a weeks-to-months onset timeline for muscle pain/myopathy.
There is no single predictable timeline for when muscle pain occurs after starting Lipitor.
The provided label excerpts do not discuss variability of onset timing.
Muscle pain or weakness after starting or increasing Lipitor, especially with dark or cola-colored urine, fever, feeling very unwell, or rapidly worsening weakness, can be a sign of a serious reaction needing urgent evaluation.
While the label mentions rhabdomyolysis with acute renal failure secondary to myoglobinuria (Section 5.1), the specific symptom cluster and urgency language (dark/cola urine, fever, feeling very unwell, rapidly worsening weakness) are not supported by the provided excerpts.
The risk of Lipitor-related muscle symptoms is higher when starting or increasing the dose.
Label excerpts provided do not explicitly state increased risk specifically at initiation/titration; they focus on higher doses and drug interactions.
The risk of Lipitor-related muscle symptoms is higher with older age.
No older-age risk factor statement is included in the provided label excerpts.
The risk of Lipitor-related muscle symptoms is higher with kidney or liver problems.
The provided excerpts mention rhabdomyolysis with acute renal failure secondary to myoglobinuria (Section 5.1) and liver dysfunction monitoring/contraindications (Sections 4 and 5.2), but they do not state that kidney or liver problems increase the risk of Lipitor-related muscle symptoms.
The risk of Lipitor-related muscle symptoms is higher with heavy alcohol use.
No heavy alcohol use risk factor statement appears in the provided label excerpts.
The risk of Lipitor-related muscle symptoms is higher with certain muscle disorders.
No statement about specific pre-existing muscle disorders increasing risk appears in the provided label excerpts.
If Lipitor is causing muscle symptoms, stopping the drug under medical guidance often improves pain over days to weeks.
The provided label excerpts do not specify expected improvement timing (days to weeks) after stopping atorvastatin.
A clinician may check muscle enzymes (such as CK) to help determine whether muscle symptoms are mild or more serious.
The provided label excerpts do not mention CK testing.
A clinician may check kidney function to help determine whether muscle symptoms are mild or more serious.
The provided label excerpts do not mention kidney function monitoring for muscle symptom severity.
Contradictions
Important Omissions
Clear labeling language that management includes temporarily withholding or discontinuing LIPITOR in patients with an acute, serious condition suggestive of myopathy (and that rhabdomyolysis with acute renal failure secondary to myoglobinuria has been reported).
Importance:
Moderate
Drug interaction specifics tied to increased myopathy/rhabdomyolysis risk with higher doses of atorvastatin and interacting agents (e.g., cyclosporine and strong CYP3A4 inhibitors) including relevant dose limits (e.g., cyclosporine limit of 10 mg once daily; caution when dose exceeds 20 mg with clarithromycin/itraconazole/protease inhibitors).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several claims are not supported by the provided label excerpts (notably onset timelines, specific symptom cluster for urgent evaluation, and multiple risk-factor assertions). These could mislead users about when/how muscle problems present and which factors raise risk, though the general advice to seek clinician evaluation for muscle symptoms is directionally consistent with withholding/discontinuing for suspected myopathy in the label.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Multiple statements about timing, symptom specifics for urgent evaluation, and several risk factors/management details (CK testing, kidney function testing, expected improvement duration) are not supported by the provided FDA label excerpts.
Suggested Improvement
Rephrase muscle-symptom content to align strictly with Section 5.1 (rare rhabdomyolysis/myopathy, interaction- and higher-dose-related risk, and temporary withholding/discontinuation for acute serious myopathy-suggestive conditions) and avoid unsupported specifics (onset days/weeks/months, symptom cluster, CK/kidney tests, alcohol/heavy alcohol, older age, kidney/liver problems as explicit risk enhancers) unless supported by the full label.